In cases where clones of cells carrying activating KRAS mutations emerge in tumours that are resistant to anti‐EGFR therapies, it is notable that most of the cells in the tumour do not carry this mutation (Misale et al., 2012). This evidence concerns the gene KRAS and neoplasm.